Nektar Therapeutics Files 8-K
Ticker: NKTR · Form: 8-K · Filed: Jun 4, 2025 · CIK: 906709
Sentiment: neutral
Topics: 8-K, disclosure, other-event
Related Tickers: NKTR
TL;DR
Nektar filed an 8-K, something happened. Details TBD.
AI Summary
Nektar Therapeutics filed an 8-K on June 4, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it is a standard disclosure required by the SEC for significant corporate occurrences. The company's principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California.
Why It Matters
This filing indicates a material event has occurred for Nektar Therapeutics, requiring public disclosure. Investors should look for further details to understand the impact on the company.
Risk Assessment
Risk Level: low — The filing itself is a procedural disclosure and does not contain negative information, thus posing a low immediate risk.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- June 4, 2025 (date) — Date of earliest event reported
- 455 Mission Bay Boulevard South (location) — Principal Executive Offices Address
- San Francisco, California (location) — Principal Executive Offices City and State
- 94158 (location) — Principal Executive Offices Zip Code
- 4154825300 (phone_number) — Registrant's telephone number
FAQ
What specific event is Nektar Therapeutics reporting in this 8-K filing?
The filing is a Form 8-K reporting an 'Other Event' as of June 4, 2025, but the specific details of the event are not provided in the text of the filing itself.
When was this 8-K filing submitted?
The filing was submitted on June 4, 2025.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the company's telephone number?
The company's telephone number, including area code, is (415) 482-5300.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding NEKTAR THERAPEUTICS (NKTR).